Introduction Executive Summary Myelofibrosis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Myelofibrosis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Myelofibrosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Myelofibrosis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Parsaclisib: Incyte Corporation • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Selinexor: Karyopharm Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I/II) • Comparative Analysis PXS-5505: Pharmaxis • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical and Discovery Stage Products • Comparative Analysis CK-0804: Cellenkos • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Myelofibrosis Key Companies Myelofibrosis Key Products Myelofibrosis- Unmet Needs Myelofibrosis- Market Drivers and Barriers Myelofibrosis- Future Perspectives and Conclusion Myelofibrosis Analyst Views Myelofibrosis Key Companies Appendix

Table 1 Total Products for Myelofibrosis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Incyte Corporation • Karyopharm Therapeutics • Celgene Corporation • PharmaEssentia • Novartis • Secura Bio • Pharmaxis • Novartis Oncology • AstraZeneca • Cellenkos • Jacobio Pharmaceuticals • Ohm oncology